Live from the NIH registry
Studies recruiting near Round Lake Beach right now
Top 25 of 472 recruiting studies, sorted by proximity — each links to its official registry page
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Smoldering Plasma Cell Myeloma
Phase 3
Interventional 288 participants sought
AMG Libertyville - Oncology — Libertyville, Illinois (9.3 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
Heart Failure
Phase 3
Interventional 1,500 participants sought
CON-10041, Island Lake, IL — Island Lake, Illinois (9.1 mi)
· Sponsor: Colorado Prevention Center
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
Phase 2
Interventional 222 participants sought
Advocate Children's Hospital-Park Ridge — Park Ridge, Illinois (28.2 mi)
· Sponsor: National Cancer Institute (NCI)
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Phase 2
Interventional 120 participants sought
Orchard Healthcare Research Inc. — Skokie, Illinois (29.8 mi)
· Sponsor: Regeneron Pharmaceuticals
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Urothelial Cancer, Bladder Cancer
Phase 2, Phase 3
Interventional 630 participants sought
Research Site — Niles, Illinois (28.7 mi)
· Sponsor: Daiichi Sankyo
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
Northwestern Medicine Grayslake Outpatient Center — Grayslake, Illinois (3.1 mi)
· Sponsor: SWOG Cancer Research Network
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase 3
Interventional 1,145 participants sought
Research Site — Niles, Illinois (28.7 mi)
· Sponsor: AstraZeneca
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Endometrial Cancer
Phase 3
Interventional 600 participants sought
Research Site — Arlington Heights, Illinois (20.7 mi)
· Sponsor: AstraZeneca
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Phase 3
Interventional 1,524 participants sought
Midwestern Regional Medical Center — Zion, Illinois (13.5 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection
Clostridium Difficile Infection Recurrence
Phase 2
Interventional 20 participants sought
Endevour Health — Skokie, Illinois (29.8 mi)
· Sponsor: Acurx Pharmaceuticals Inc.
Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3
Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma
Phase 2
Interventional 100 participants sought
City of Hope at Chicago — Zion, Illinois (13.5 mi)
· Sponsor: City of Hope Medical Center
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
Chronic Kidney Disease
Phase 2
Interventional 465 participants sought
Endeavor Health — Skokie, Illinois (29.8 mi)
· Sponsor: Novo Nordisk A/S
E-Mindfulness Approaches for Living After Breast Cancer
Breast Cancer, Depression
Phase 3
Interventional 402 participants sought
Northwestern Medicine Grayslake Outpatient Center — Grayslake, Illinois (3.1 mi)
· Sponsor: NRG Oncology
Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone
Glaucoma, Open-angle, Ocular Hypertension (OHT)
Phase 4
Interventional 132 participants sought
Glaukos Investigator Site — Kenosha, Wisconsin (19.4 mi)
· Sponsor: Glaukos Corporation
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8
Phase 3
Interventional 356 participants sought
Northwestern Medicine Grayslake Outpatient Center — Grayslake, Illinois (3.1 mi)
· Sponsor: NRG Oncology
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Phase 3
Interventional 750 participants sought
Illinois Cancer Specialists — Niles, Illinois (28.7 mi)
· Sponsor: Amgen
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Systemic Lupus Erythematosus
Phase 3
Interventional 550 participants sought
Robert A Hozman MD SC — Skokie, Illinois (29.8 mi)
· Sponsor: Novartis Pharmaceuticals
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Phase 3
Interventional 1,530 participants sought
Illinois Cancer Specialists (ICS) ( Site 8010) — Arlington Heights, Illinois (20.7 mi)
· Sponsor: Merck Sharp & Dohme LLC
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Diabetes Mellitus, Type 2, Hypertension
Phase 3
Interventional 11,800 participants sought
Clinical Investigation Specialists, Inc.-Kenosha-69111 — Kenosha, Wisconsin (19.4 mi)
· Sponsor: Boehringer Ingelheim
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
Phase 2
Interventional 1,431 participants sought
Midwest Digestive Health & Nutrition — Des Plaines, Illinois (25.9 mi)
· Sponsor: Eli Lilly and Company
Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction
Phase 3
Interventional 2,000 participants sought
Alexian Brothers Medical Center — Elk Grove Village, Illinois (26.5 mi)
· Sponsor: Uppsala University
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Ulcerative Colitis, Crohn's Disease
Phase 3
Interventional 240 participants sought
Advocate Children's Hospital - Park Ridge - PIN — Park Ridge, Illinois (28.2 mi)
· Sponsor: Takeda
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Phase 2
Interventional 2,000 participants sought
Northwestern Medicine Grayslake Outpatient Center — Grayslake, Illinois (3.1 mi)
· Sponsor: National Cancer Institute (NCI)
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients
Irritability Associated With Autism Spectrum Disorder
Phase 3
Interventional 160 participants sought
Revive Research Institute — Elgin, Illinois (25.7 mi)
· Sponsor: Intra-Cellular Therapies, Inc.
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Phase 3
Interventional 600 participants sought
City of Hope® Cancer Center Chicago — Zion, Illinois (13.5 mi)
· Sponsor: Hoffmann-La Roche